p53 HDR Plasmid (h) cDNA from Santa Cruz Biotechnology, Inc.

Product Specs
Itemp53 HDR Plasmid (h) cDNA
CompanySanta Cruz Biotechnology, Inc.
Price $437.00Supplier Page View Company Product Page
Catalog Numbersc-416469-HDR
NCBI Gene AliasesBCC7, BMFS5, LFS1, P53, TRP53
NCBI Full Gene Nametumor protein p53
Specieshuman
TypePlasmid
Quantity20 µg

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Hepatic p53 is regulated by transcription factor FOXO1 and acutely controls glycogen homeostasisThe Journal of biological chemistrySeptember 1, 2022Oster M, Galhuber M, Krstic J, Steinhoff JS, Lenihan-Geels G, Wulff S, Kiefer MF, Petricek KM, Wowro SJ, Flores RE, et al.

(2) Complementary omics strategies to dissect p53 signaling networks under nutrient stressCellular and molecular life sciences : CMLSMay 30, 2022Galhuber M, Michenthaler H, Heininger C, Reinisch I, Nössing C, Krstic J, Kupper N, Moyschewitz E, Auer M, Heitzer E, et al.

(3) Activation of the atypical NF-κB pathway induced by ionizing radiation is not affected by the p53 statusActa biochimica PolonicaFebruary 7, 2022Zając G, Rusin M, Łasut-Szyszka B, Puszyński K, Widłak P.

(4) Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergismScience advancesJanuary 21, 2022Krstic J, Reinisch I, Schindlmaier K, Galhuber M, Riahi Z, Berger N, Kupper N, Moyschewitz E, Auer M, Michenthaler H, et al.

(5) Mutant p53 elicits context-dependent pro-tumorigenic phenotypesOncogeneJanuary 1, 2022McCann JJ, Vasilevskaya IA, McNair C, Gallagher P, Neupane NP, de Leeuw R, Shafi AA, Dylgjeri E, Mandigo AC, Schiewer MJ, et al.transfection in antibiotic-free media. CRISPR/Cas9 TP53 KO plasmid (sc-416469) and the associated HDR plasmid (sc-416469-HDR; Santa Cruz Biotechnology) were co-transfected, and 48 h post-transfection cells began selection with

(6) Transcriptome Analysis of Cells Exposed to Actinomycin D and Nutlin-3a Reveals New Candidate p53-Target Genes and Indicates That CHIR-98014 Is an Important Inhibitor of p53 ActivityInternational journal of molecular sciencesOctober 14, 2021Łasut-Szyszka B, Małachowska B, Gdowicz-Kłosok A, Krześniak M, Głowala-Kosińska M, Zajkowicz A, Rusin M.

(7) AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylaseProceedings of the National Academy of Sciences of the United States of AmericaSeptember 7, 2021Yoshihama Y, LaBella KA, Kim E, Bertolet L, Colic M, Li J, Shang X, Wu CJ, Spring DJ, Wang YA, et al.

(8) iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4Nature communicationsJune 15, 2021Chen D, Chu B, Yang X, Liu Z, Jin Y, Kon N, Rabadan R, Jiang X, Stockwell BR, Gu W.

(9) Proteomic Analysis Uncovers Measles Virus Protein C Interaction With p65-iASPP Protein ComplexMolecular & cellular proteomics : MCPJanuary 1, 2021Meignié A, Combredet C, Santolini M, Kovács IA, Douché T, Gianetto QG, Eun H, Matondo M, Jacob Y, Grailhe R, et al.

(10) Influence of nonprotective autophagy and the autophagic switch on sensitivity to cisplatin in non-small cell lung cancer cellsBiochemical pharmacologyMay 1, 2020Patel NH, Xu J, Saleh T, Wu Y, Lima S, Gewirtz DA.(Santa Cruz Biotechnologies; cat #sc-416469) and 1 μg a homology directed repair plasmid (Santa Cruz, cat. #sc-416469-HDR) expressing a puromycin selection marker. Cells were transfected using PolyJet reagent (Signagen) following

(11) PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growthNature communicationsDecember 20, 2019Cai W, Su L, Liao L, Liu ZZ, Langbein L, Dulaimi E, Testa JR, Uzzo RG, Zhong Z, Jiang W, et al.

(12) A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variantsScientific reportsNovember 19, 2019Ticha I, Hojny J, Michalkova R, Kodet O, Krkavcova E, Hajkova N, Nemejcova K, Bartu M, Jaksa R, Dura M, et al.

(13) Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null GliomaCancer cellJune 10, 2019Chen P, Zhao D, Li J, Liang X, Li J, Chang A, Henry VK, Lan Z, Spring DJ, Rao G, et al.

(14) ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathwayNature cell biologyMay 1, 2019Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, Song S, Tavana O, Gu W.

(15) p53 Represses the Mevalonate Pathway to Mediate Tumor SuppressionCellJanuary 24, 2019Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP 4th, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, et al.

(16) Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCsAmerican journal of cancer researchJanuary 1, 2019Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, et al.

(17) BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screeningAmerican journal of cancer researchJanuary 1, 2019Ding J, Wu S, Zhang C, Garyali A, Martinez-Ledesma E, Gao F, Pokkulandra A, Li X, Bristow C, Carugo A, et al.

(18) Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramersGenes & developmentMarch 1, 2018Katz C, Low-Calle AM, Choe JH, Laptenko O, Tong D, Joseph-Chowdhury JN, Garofalo F, Zhu Y, Friedler A, Prives C.

(19) TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibitionAutophagyJanuary 1, 2018Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, et al.

(20) Dysfunction of the MDM2/p53 axis is linked to premature agingThe Journal of clinical investigationOctober 2, 2017Lessel D, Wu D, Trujillo C, Ramezani T, Lessel I, Alwasiyah MK, Saha B, Hisama FM, Rading K, Goebel I, et al.

Be the First to Write a Review!